228 related articles for article (PubMed ID: 24064975)
21. Comparative proteomics analysis of human osteosarcomas and benign tumor of bone.
Li Y; Liang Q; Wen YQ; Chen LL; Wang LT; Liu YL; Luo CQ; Liang HZ; Li MT; Li Z
Cancer Genet Cytogenet; 2010 Apr; 198(2):97-106. PubMed ID: 20362224
[TBL] [Abstract][Full Text] [Related]
22. Ephrin-A1 inhibits NSCLC tumor growth via induction of Cdx-2 a tumor suppressor gene.
Sukka-Ganesh B; Mohammed KA; Kaye F; Goldberg EP; Nasreen N
BMC Cancer; 2012 Jul; 12():309. PubMed ID: 22824143
[TBL] [Abstract][Full Text] [Related]
23. KDM6B-mediated histone demethylation of LDHA promotes lung metastasis of osteosarcoma.
Jiang Y; Li F; Gao B; Ma M; Chen M; Wu Y; Zhang W; Sun Y; Liu S; Shen H
Theranostics; 2021; 11(8):3868-3881. PubMed ID: 33664867
[No Abstract] [Full Text] [Related]
24. Comparative membrane proteomics analyses of breast cancer cell lines to understand the molecular mechanism of breast cancer brain metastasis.
Peng W; Zhang Y; Zhu R; Mechref Y
Electrophoresis; 2017 Sep; 38(17):2124-2134. PubMed ID: 28523741
[TBL] [Abstract][Full Text] [Related]
25. Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder.
Abraham S; Knapp DW; Cheng L; Snyder PW; Mittal SK; Bangari DS; Kinch M; Wu L; Dhariwal J; Mohammed SI
Clin Cancer Res; 2006 Jan; 12(2):353-60. PubMed ID: 16428472
[TBL] [Abstract][Full Text] [Related]
26. YSA-conjugated mesoporous silica nanoparticles effectively target EphA2-overexpressing breast cancer cells.
Liu Z; Tao Z; Zhang Q; Wan S; Zhang F; Zhang Y; Wu G; Wang J
Cancer Chemother Pharmacol; 2018 Apr; 81(4):687-695. PubMed ID: 29392452
[TBL] [Abstract][Full Text] [Related]
27. Overexpression of KH-type splicing regulatory protein regulates proliferation, migration, and implantation ability of osteosarcoma.
Pruksakorn D; Teeyakasem P; Klangjorhor J; Chaiyawat P; Settakorn J; Diskul-Na-Ayudthaya P; Chokchaichamnankit D; Pothacharoen P; Srisomsap C
Int J Oncol; 2016 Sep; 49(3):903-12. PubMed ID: 27573585
[TBL] [Abstract][Full Text] [Related]
28. EphA2 receptor activation by monomeric Ephrin-A1 on supported membranes.
Xu Q; Lin WC; Petit RS; Groves JT
Biophys J; 2011 Dec; 101(11):2731-9. PubMed ID: 22261062
[TBL] [Abstract][Full Text] [Related]
29. Up-regulation of EphA2 and down-regulation of EphrinA1 are associated with the aggressive phenotype and poor prognosis of malignant glioma.
Li X; Wang L; Gu JW; Li B; Liu WP; Wang YG; Zhang X; Zhen HN; Fei Z
Tumour Biol; 2010 Oct; 31(5):477-88. PubMed ID: 20571968
[TBL] [Abstract][Full Text] [Related]
30. EphA2-induced angiogenesis in ewing sarcoma cells works through bFGF production and is dependent on caveolin-1.
Sáinz-Jaspeado M; Huertas-Martinez J; Lagares-Tena L; Martin Liberal J; Mateo-Lozano S; de Alava E; de Torres C; Mora J; Del Muro XG; Tirado OM
PLoS One; 2013; 8(8):e71449. PubMed ID: 23951165
[TBL] [Abstract][Full Text] [Related]
31. Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype.
Paraiso KH; Das Thakur M; Fang B; Koomen JM; Fedorenko IV; John JK; Tsao H; Flaherty KT; Sondak VK; Messina JL; Pasquale EB; Villagra A; Rao UN; Kirkwood JM; Meier F; Sloot S; Gibney GT; Stuart D; Tawbi H; Smalley KS
Cancer Discov; 2015 Mar; 5(3):264-73. PubMed ID: 25542447
[TBL] [Abstract][Full Text] [Related]
32. Small molecules can selectively inhibit ephrin binding to the EphA4 and EphA2 receptors.
Noberini R; Koolpe M; Peddibhotla S; Dahl R; Su Y; Cosford ND; Roth GP; Pasquale EB
J Biol Chem; 2008 Oct; 283(43):29461-72. PubMed ID: 18728010
[TBL] [Abstract][Full Text] [Related]
33. Biological and structural characterization of glycosylation on ephrin-A1, a preferred ligand for EphA2 receptor tyrosine kinase.
Ferluga S; Hantgan R; Goldgur Y; Himanen JP; Nikolov DB; Debinski W
J Biol Chem; 2013 Jun; 288(25):18448-57. PubMed ID: 23661698
[TBL] [Abstract][Full Text] [Related]
34. Higher expression of EphA2 and ephrin-A1 is related to favorable clinicopathological features in pathological stage I non-small cell lung carcinoma.
Ishikawa M; Miyahara R; Sonobe M; Horiuchi M; Mennju T; Nakayama E; Kobayashi M; Kikuchi R; Kitamura J; Imamura N; Huang CL; Date H
Lung Cancer; 2012 Jun; 76(3):431-8. PubMed ID: 22236865
[TBL] [Abstract][Full Text] [Related]
35. Ephrin A4 expression in osteosarcoma, impact on prognosis, and patient outcome.
Abdou AG; Abd el-Wahed MM; Asaad NY; Samaka RM; Abdallaha R
Indian J Cancer; 2010; 47(1):46-52. PubMed ID: 20071790
[TBL] [Abstract][Full Text] [Related]
36. Lithocholic acid-tryptophan conjugate (UniPR126) based mixed micelle as a nano carrier for specific delivery of niclosamide to prostate cancer via EphA2 receptor.
Jannu AK; Puppala ER; Gawali B; Syamprasad NP; Alexander A; Marepally S; Chella N; Gangasani JK; Naidu VGM
Int J Pharm; 2021 Aug; 605():120819. PubMed ID: 34166727
[TBL] [Abstract][Full Text] [Related]
37. Ephrin-As, Eph receptors and integrin α3 interact and colocalise at membrane protrusions of U251MG glioblastoma cells.
Makarov A; Ylivinkka I; Nyman TA; Hyytiäinen M; Keski-Oja J
Cell Biol Int; 2013 Oct; 37(10):1080-8. PubMed ID: 23686814
[TBL] [Abstract][Full Text] [Related]
38. Proteomic approach toward molecular backgrounds of drug resistance of osteosarcoma cells in spheroid culture system.
Arai K; Sakamoto R; Kubota D; Kondo T
Proteomics; 2013 Aug; 13(15):2351-60. PubMed ID: 23712969
[TBL] [Abstract][Full Text] [Related]
39. Spatial organization-dependent EphA2 transcriptional responses revealed by ligand nanocalipers.
Verheyen T; Fang T; Lindenhofer D; Wang Y; Akopyan K; Lindqvist A; Högberg B; Teixeira AI
Nucleic Acids Res; 2020 Jun; 48(10):5777-5787. PubMed ID: 32352518
[TBL] [Abstract][Full Text] [Related]
40. Chemical Proteomics and Structural Biology Define EPHA2 Inhibition by Clinical Kinase Drugs.
Heinzlmeir S; Kudlinzki D; Sreeramulu S; Klaeger S; Gande SL; Linhard V; Wilhelm M; Qiao H; Helm D; Ruprecht B; Saxena K; Médard G; Schwalbe H; Kuster B
ACS Chem Biol; 2016 Dec; 11(12):3400-3411. PubMed ID: 27768280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
